Pioglitazone in acromegaly - An open-label, prospective study

Clinical Endocrinology

Volumn 77, Issue 4, 2012, Pages 575-578

  Kim, David D W ^a   Goh, Jovina ^a   Panossian, Zaven ^a   Gamble, Greg ^b   Holdaway, Ian ^a   Grey, Andrew ^b  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CABERGOLINE; GROWTH HORMONE; OCTREOTIDE; PIOGLITAZONE; SOMATOMEDIN C;

ACROMEGALY; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; DEMOGRAPHY; DISEASE ACTIVITY; DRUG DOSE INCREASE; FEMALE; GROWTH HORMONE BLOOD LEVEL; HUMAN; MALE; MAXIMUM TOLERATED DOSE; OPEN STUDY; ORAL GLUCOSE TOLERANCE TEST; PATIENT COMPLIANCE; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ACROMEGALY; ADULT; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; THIAZOLIDINEDIONES;

EID: 84867288293     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2012.04411.x     Document Type: Article

References (18)

1. Rajasoorya, C., Holdaway, I.M., Wrightson, P. et al. (1994) Determinants of clinical outcome and survival in acromegaly. Clinical Endocrinology, 41, 95-102.
2. Holdaway, I.M., Rajasoorya, R.C. & Gamble, G.D. (2004) Factors influencing mortality in acromegaly. Journal of Clinical Endocrinology and Metabolism, 89, 667-674.
3. Holdaway, I.M., Bolland, M.J. & Gamble, G.D. (2008) A metaanalysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. European Journal of Endocrinology, 159, 89-95.
4. Melmed, S. (2006) Acromegaly. New England Journal of Medicine, 355, 2558-2573.
5. Minniti, G., Traish, D., Ashley, S. et al. (2005) Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: update after an additional 10 years. Journal of Clinical Endocrinology and Metabolism, 90, 800-804.
6. Lecka-Czernik, B., Ackert-Bicknell, C., Adamo, M.L. et al. (2007) Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo. Endocrinology, 148, 903-911.
7. Heaney, A.P., Fernando, M. & Melmed, S. (2003) PPAR-gamma receptor ligands: novel therapy for pituitary adenomas. Journal of Clinical Investigation, 111, 1381-1388.
8. Bogazzi, F., Ultimieri, F., Raggi, F. et al. (2004) PPARgamma inhibits GH synthesis and secretion and increases apoptosis of pituitary GH-secreting adenomas. European Journal of Endocrinology/European Federation of Endocrine Societies, 150, 863-875.
9. Glintborg, D., Støving, R.K., Hagen, C. et al. (2005) Pioglitazone treatment increases spontaneous growth hormone (GH) secretion and stimulated GH levels in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism, 90, 5605-5612.
10. Gradiser, M., Matovinovic, M. & Vrkljan, M. (2007) Decrease in growth hormone and insulin-like growth factor (IGF)-1 release and amelioration of acromegaly features after rosiglitazone treatment of type 2 diabetes mellitus a patient with acromegaly. Croatian Medical Journal, 48, 87-91.
11. Bastemir, M., Akin, F. & Yaylali, G.F. (2007) The PPAR-gamma activator rosiglitazone fails to lower plasma growth hormone and insulin-like growth factor-1 levels in patients with acromegaly. Neuroendocrinology, 86, 119-123.
12. Bogazzi, F., Rossi, G., Lombardi, M. et al. (2011) Effect of rosiglitazone on serum IGF-I concentrations in uncontrolled acromegalic patients under conventional medical therapy: results from a pilot phase 2 study. Journal of Endocrinological Investigation, 34, e43-e51.
13. Nissen, S.E. & Wolski, K. (2010) Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Archives of Internal Medicine, 170, 1191-1201.
14. Cohen, D. (2010) European regulatory body recommends suspension of rosiglitazone. BMJ, 341, c5291.
15. Rosen, C.J. (2010) Revisiting the rosiglitazone story - lessons learned. New England Journal of Medicine, 363, 803-806.
16. Heaney, A.P. (2004) PPAR-gamma in Cushing's disease. Pituitary, 7, 265-269.
17. Suri, D. & Weiss, R.E. (2005) Effect of pioglitazone on adrenocorticotropic hormone and cortisol secretion in Cushing's disease. Journal of Clinical Endocrinology and Metabolism, 90, 1340-1346.
18. Giraldi, F.P., Scaroni, C., Arvat, E. et al. (2006) Effect of protracted treatment with rosiglitazone, a PPARc agonist, in patients with Cushing's disease. Clinical Endocrinology, 64, 219-224.